Malaisie - anglais - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

johnson & johnson sdn bhd - prucalopride succinate -

Malaisie - anglais - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

johnson & johnson sdn bhd - prucalopride succinate -

Malaisie - anglais - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

dksh malaysia sdn bhd - prucalopride succinate -

Malaisie - anglais - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

dksh malaysia sdn bhd - prucalopride succinate -

Australie - anglais - Department of Health (Therapeutic Goods Administration)

forest herbs research ltd - aniseed powder,pseudowintera colorata -

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

viatris limited - cefaclor monohydrate 26.86 mg/ml equivalent to cefaclor 25 mg/ml - granules for oral suspension - 125 mg/5ml - active: cefaclor monohydrate 26.86 mg/ml equivalent to cefaclor 25 mg/ml excipient: dimeticone erythrosine methylcellulose sodium laurilsulfate starch strawberry flavour 052312 ap0551 sucrose xanthan gum - cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated micro-organisms: lower respiratory infections, including pneumonia caused by s. pneumoniae, h. influenzae (including both ampicillin-sensitive and ampicillin-resistant strains), and s. pyogenes (group a beta- haemolytic streptococci), m.catarrhalis, acute bronchitis, and acute exacerbations of chronic bronchitis. upper respiratory infections, including pharyngitis and tonsillitis caused by s. pyogenes (group a beta-haemolytic streptococci) and m. catarrhalis. otitis media caused by s. pneumoniae, h. influenzae (including both ampicillin-sensitive and ampicillin-resistant strains) staphylococci, and s. pyogenes (group a beta-haemolytic streptococci), and m. catarrhalis. skin and soft-tissue infections caused by staphylococcus aureus (including ?-lactamase producing strains), s. pyogenes (group a beta-haemolytic streptococci) and staphylococcus epidermidis (including ?-lactamase producing strains). urinary tract infections, including pyelonephritis and cystitis caused by e. coli, p, mirabilis, klebsiella sp" and coagulase-negative staphylococci. note: cefaclor has been found to be effective in both acute and chronic urinary tract infections; sinusitis; gonococcal urethritis. skin and skin structure infections caused by staphylococcus aureus and s. pyogenes (group a beta-haemolytic streptococci). sinusitis. gonococcal urethritis, but appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefaclor. therapy may be started while awaiting the results of these studies. once these results become available, antimicrobial therapy should be adjusted accordingly.

Irlande - anglais - HPRA (Health Products Regulatory Authority)

vetoquinol ireland limited - florfenicol - solution for injection - 300 milligram(s)/millilitre - florfenicol

Singapour - anglais - HSA (Health Sciences Authority)

dch auriga singapore - prucalopride succinate 1.321mg eqv prucalopride - tablet, film coated - 1mg - prucalopride succinate 1.321mg eqv prucalopride 1mg

Singapour - anglais - HSA (Health Sciences Authority)

dch auriga singapore - prucalopride succinate 2.642mg eqv prucalopride - tablet, film coated - 2mg - prucalopride succinate 2.642mg eqv prucalopride 2mg

Canada - anglais - Health Canada

apotex inc - azithromycin (azithromycin isopropanolate monohydrate) - capsule - 250mg - azithromycin (azithromycin isopropanolate monohydrate) 250mg - other macrolides